

Paula Cunnea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4167056/publications.pdf>

Version: 2024-02-01

32
papers

751
citations

759233

12
h-index

552781

26
g-index

32
all docs

32
docs citations

32
times ranked

1584
citing authors

#	ARTICLE	IF	CITATIONS
1	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. <i>Nature Communications</i> , 2019, 10, 764.	12.8	130
2	Increased Expression of Endoplasmic Reticulum Stress-Related Signaling Pathway Molecules in Multiple Sclerosis Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 200-211.	1.7	99
3	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2213-2222.	7.0	83
4	Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 808-818.	3.0	64
5	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. <i>Annals of Surgical Oncology</i> , 2019, 26, 2943-2951.	1.5	54
6	The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis. <i>Biochemical Society Transactions</i> , 2009, 37, 329-331.	3.4	52
7	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 31593-31603.	1.8	39
8	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	4.5	30
9	Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels. <i>Acta Neuropathologica</i> , 2010, 119, 601-615.	7.7	28
10	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. <i>Oncotarget</i> , 2015, 6, 41736-41749.	1.8	22
11	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF- κ B. <i>Oncogene</i> , 2021, 40, 1077-1090.	5.9	18
12	Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. , 2021, 4, 573-595.		17
13	Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). <i>British Journal of Cancer</i> , 2022, 126, 1047-1054.	6.4	17
14	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. <i>Cancer Letters</i> , 2019, 459, 1-12.	7.2	16
15	Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2021, 124, 1286-1293.	6.4	13
16	Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems. <i>Frontiers in Oncology</i> , 2014, 4, 81.	2.8	12
17	The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 1570-1579.	7.0	12
18	Ovarian cancer stem cells: ready for prime time?. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 895-899.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients. <i>Scientific Reports</i> , 2018, 8, 14695.	3.3	7
20	The passive biomechanics of human pelvic collecting lymphatic vessels. <i>PLoS ONE</i> , 2017, 12, e0183222.	2.5	6
21	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 1076.	3.7	5
22	Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 270, 212-220.	1.1	5
23	Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients. <i>PLoS ONE</i> , 2020, 15, e0230092.	2.5	4
24	Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, 013002.	2.6	2
25	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. <i>Cancers</i> , 2021, 13, 3349.	3.7	2
26	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. <i>Frontiers in Oncology</i> , 2022, 12, 837233.	2.8	2
27	Abstract 260: Elucidating the roles of the alternatively spliced transcripts of Septin 9. , 2010, , .		1
28	Characterising phenotypically relevant intratumoural heterogeneity in high grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16569-e16569.	1.6	1
29	Abstract 5012: Regulation of splicing of SEPT9 in health and disease. , 2011, , .		0
30	Molecular physiology monitoring of ovarian cancer ex vivo.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16567-e16567.	1.6	0
31	Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway. , 2015, , .		0
32	Abstract A2-13: Targeting genomic instability to identify molecular drivers of poor prognosis in cancer.. , 2015, , .		0